新疆地区三级甲等医院住院慢性心力衰竭患者临床特征及诊治现状调查研究

doi:10.20047/j.issn1673-7210.2022.30.15

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (608 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the demographic data, clinical characteristics, and management of inpatients with chronic heart failure (CHF) in a tertiary hospital in Xinjiang. Methods This study was a cross-sectional study. From January 2018 to September 2020, 1 500 patients with CHF who were continuously hospitalized in the provincial tertiary hospitals in Xinjiang (the First Affiliated Hospital of Xinjiang Medical University, the People’s Hospital of Xinjiang Uygur Autonomous Region, and the Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region) and three municipal tertiary hospitals (the Second People’s Hospital of Kashgar, Yili Prefecture People’s Hospital, Changji Prefecture Traditional Chinese Medicine Hospital) were selected. The general information, risk factors, etiology of CHF, examination results, drug use, and other clinical data of the selected patients were collected. Results A total of 1 451 CHF patients were finally included, including 967 males; the age was (64.14±13.13) years; the median hospital stay was nine days. Patients with CHF with reduced ejection fraction (HFrEF) and class Ⅲ cardiac function accounted for the highest proportions. The rates of ACEI/ ARB/ARNI, β-blocker, and aldosterone receptor antagonist use in HFrEF patients were 87.2%, 89.5%, and 88.0%, respectively. The proportion of CHF patients hospitalized in provincial tertiary hospitals was higher than that of municipal tertiary hospitals, while the length of stay was shorter than that of century tertiary hospitals, and the differences were statistically significant (P ＜ 0.05). The rate of NT-Pro BNP/BNP examination in CHF patients in provincial tertiary hospitals, patients with HFrEF and cardiac function grade Ⅳ, patients undergoing pacing intervention, coronary intervention or bypass, and the proportion of hyperuricemia, anemia, and renal insufficiency in provincial tertiary hospitals were higher in the municipal tertiary hospital (P ＜ 0.05). The proportion of HFrEF patients in provincial tertiary hospitals were higher than that of municipal tertiary hospitals; the proportion of patients using aldosterone receptor antagonists was lower than that of municipal tertiary hospitals (P ＜ 0.05). Conclusion Coronary heart disease is the main cause of inpatient CHF in the top three hospitals in Xinjiang. CHF patients hospitalized in provincial tertiary hospitals were older and had worse cardiac function. There was no significant difference in the proportion of standardized drug use recommended by the guidelines for HFrEF patients hospitalized in provincial and municipal tertiary hospitals.

Key words： Chronic heart failure Diagnosis Treatment Xinjiang area

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Refukaiti Abuduhalike Kailibinuer Abuduhalike SUN Juan Ailiman Mahemuti

Cite this article:

Refukaiti Abuduhalike Kailibinuer Abuduhalike SUN Juan Ailiman Mahemuti. Investigation and research on clinical characteristics, diagnosis, and treatment status of chronic heart failure patients in tertiary and first-class hospitals in Xinjiang area[J]. 中国医药导报, 2022, 19(30): 70-74.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.30.15 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I30/70

[1] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global，regional，and national incidence，prevalence，and years lived with disability for 354 diseases and injuries for 195 countries and territories，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2018，392（10159）：1789-1858.
[2] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志，2020，35（9）：833- 854.
[3] Groenewegen A，Rutten FH，Mosterd A，et al. Epidemiology of heart failure [J]. Eur J Heart Fail，2020，22（8）：1342- 1356.
[4] Seferovi■ PM，Vardas P，Jankowska EA，et al. The Heart Failure Association Atlas：Heart Failure Epidemiology and Management Statistics 2019 [J]. Eur J Heart Fail，2021， 23：906-914.
[5] Groenewegen A，Rutten FH，Mosterd A，et al. Epidemiology of heart failure [J]. Eur J Heart Fail，2020，22（8）：1342- 1356.
[6] Roger VL. Epidemiology of Heart Failure：A Contemporary Perspective [J]. Circ Res，2021，128（10）：1421-1434.
[7] Tromp J，Ferreira JP，Janwanishstaporn S，et al. Heart failure around the world [J]. Eur J Heart Fail，2019，21（10）：1187-1196.
[8] 中华医学会心血管病学分会心衰学组，中国医师协会心衰专业委员会，中华心血管病杂志编辑委员会.中国心衰诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[9] Dunlay SM，Roger VL，Killian JM，et al. Advanced Heart Failure Epidemiology and Outcomes：A Population-Based Study [J]. JACC Heart Fail，2021，9（10）：722-732.
[10] Liew D，Audehm RG. Epidemiology of heart failure：Study of Heart failure in the Australian Primary carE setting （SHAPE） [J]. ESC Heart Failure，2020，7（6）：3871-3880.
[11] Koirala B，Dennison Himmelfarb CR，Koirala B，et al. Epidemiology and Management of Heart Failure in Nepal [J]. J Card Fail，2019，25（10）：846-848.
[12] G?觟k G，K?覦l?覦?觭 S，Sinan Y，et al. Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced，mid-range and preserved ejection fraction [J]. Heart Lung，2020，49（5）：495-500.
[13] Fr?觟hlich H，Rosenfeld N，T?覿ger T，et al. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe [J]. Heart，2019，105（16）：1252-1259.
[14] Zhang Y，Zhang J，Butler J，et al. Contemporary Epidemiology，Management，and Outcomes of Patients Hospitalized for Heart Failure in China：Results From the China Heart Failure （China-HF） Registry [J]. J Card Fail，2017，23（12）：868-875.
[15] Lam CSP，Arnott C，Beale AL，et al. Sex differences in heart failure [J]. Eur Heart J，2019，40（47）：3859-3868.
[16] Yu Y，Gupta A，Wu C，et al. Characteristics，Management，and Outcomes of Patients Hospitalized for Heart Failure in China：The China PEACE Retrospective Heart Failure Study [J]. J Am Heart Assoc，2019，8（17）：e012884.
[17] AlFaleh H，Elasfar AA，Ullah A，et al. Worsening heart failure in ‘real-world’ clinical practice：predictors and prognostic impact [J]. Eur J Heart Fail，2017，19（8）：987-995.
[18] Balsam P，Ozierański K，Kap?覥on-Cie■licka A，et al. Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries [J]. Pol Arch Intern Med，2019，129（2）：106-116.
[19] Lund LH，Claggett B，Liu J，et al. Heart failure with mid-range ejection fraction in CHARM：characteristics，outcomes and effect of candesartan across the entire ejection fraction spectrum [J]. Eur J Heart Fail，2018，20（8）：1230- 1239.
[20] Elasfar AA，Alhabeeb W，Elasfar S. Heart Failure in the Middle East Arab Countries：Current and Future Perspectives [J]. J Saudi Heart Assoc，2020，32（2）：236-241.
[21] 蒋华，张红威，周贤惠，等.新疆地区不同级别医院慢性心衰患者临床特征及治疗现状分析[J].中国循环杂志，2015，30（12）：1186-1190.
[22] McMurray JJ，Packer M，Desai AS，et al. Angiotensin- neprilysin inhibition versus enalapril in heart failure [J]. N Engl J Med，2014，371（11）：993-1004.
[23] Wiviott SD，Raz I，Bonaca MP，et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes [J]. N Engl J Med，2019，380（4）：347-357.
[24] Armstrong PW，Roessig L，Patel MJ，et al. A Multicenter，Randomized，Double-Blind，Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator：The VICTORIA Trial [J]. JACC Heart Fail，2018，6（2）：96-104.
[25] Teng TK，Tromp J，Tay WT，et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry：a cohort study [J]. Lancet Glob Health，2018，6（9）：e1008-e1018.
[26] Gan T，Zhang Y，Liu N，et al. Gap Between Clinical Practice and Guidelines：A National Survey of the Knowledge of Recommended Heart Failure Guidelines Among Chinese Physicians [J]. Qual Manag Health Care，2017，26（4）：196-204.